Focusing on the Role of the Advanced Bladder Cancer Care Team: Case Studies on Managing irAEs
Join Drs. Neal Shore, Gautam Jayram, and Nurse Tanya O’Neal as they discuss clinical considerations for managing immune-related adverse events that may occur at any time during therapy and, as of yet, there is no reliable means to predict who will develop them. If irAEs do develop, it is essential to arrive at an early diagnosis and use aggressive systemic corticosteroids when necessary to prevent life-threatening consequences. Therefore, it is paramount to educate patients, caregivers, and other providers involved on what to expect and follow up with patients often to ensure optimal outcomes for patients on immunotherapy agents.
This activity is presented by Creative Educational Concepts and Bladder Cancer Advocacy Network and supported by independent educational grants from AstraZeneca and Genentech.
To complete the other activities in this series please click here.
Urology community physicians, physician assistants, nurse practitioners, nurses, and pharmacists.
- Anticipate and appropriately manage adverse events that may occur in the use of ICIs in the patient with UBC.
- Incorporate available patient education for immunotherapies used in UBC, including education on immune-related adverse events and role of the interprofessional bladder cancer team.
Neal Shore, MD, FACS (Activity Chair)
Director, CPI, Carolina Urologic Research Center
Atlantic Urology Clinics
Myrtle Beach, South Carolina
Robert Dreicer, MD, MS, MACP, FASCO
Professor of Medicine and Urology
University of Virginia School of Medicine
Gautam Jayram, MD
Tanya O’Neal, RN, BSN, MSN
Senior Research Nurse
Johns Hopkins University
In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.
Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.
Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
Susan H. Gitzinger, PharmD, MPH–has disclosed she has no financial disclosures in relation to this activity.
Kirollos S. Hanna, PharmD, BCPS, BCOP–has disclosed that he is a consultant for Seattle Genetics and his a member of the speakers' burueau for Astellas, Bristol-Myers Squibb, and Seattle Genetics.
Neal Shore, MD, FACS–has disclosed that he is a consultant and receives grant/research support from Abbvie, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Color Genomics, Dendreon, Ferring, Genentech, Genomic Health, Genzyme, Innovia, Invitae, Janssen, Merck, Myriad, Nymox, Panacea, Pfizer, Roche, Sanofi, and Tolmar.
Robert Dreicer, MD, MS, MACP, FASCO–has disclosed that he is a consultant for Astellas, Eisai, EMD Serono Genetech, Merck, Pfizer, and Seattle Genetics.
Gautam Jayram, MD–has disclosed he has no financial disclosures in relation to this activity.
Tanya O’Neal, RN, BSN, MSN–has disclosed she has no financial disclosures in relation to this activity.
Bishoy Morris Faltas, MD–has no relevant financial relationships to disclose in relation to the content of this activity.
Sami Larson, PharmD-has no relevant financial relationships to disclose in relation to the content of this activity.
Caroline Pratz, CRNP-has no relevant financial relationships to disclose in relation to the content of this activity.
In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CEC designates this live educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This application-based activity is approved for 1.0 contact hour (.10 CEUs) of continuing pharmacy education credit (JA0007101-0000-20-020-H01-P)
This activity is designated for 1.0 contact hour.
Upon completion of a CE request form, statements of credit for physicians, physician assistants, and nurses will be issued within 30 business days. Pharmacy credit will be reported directly to the National Association of Boards of Pharmacy® NABP® CPE Monitor electronic CE tracking system.
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation